Blueprint Medicines (BPMC) Earnings Date, Estimates & Call Transcripts → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free bpmc Stock Alerts $94.86 +0.07 (+0.07%) (As of 03/28/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 2EstimatedActual EPS (Feb. 15) -$1.82 Beat By $0.22 Consensus EPS (Feb. 15) -$2.04 Read Call TranscriptListen to Call Get Blueprint Medicines Earnings AlertsEnter your email address below to receive the latest news and earnings results for BPMC and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBPMC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BPMC Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… Blueprint Medicines Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243($1.89)($1.31)($1.67) Q2 20243($1.56)($0.88)($1.33) Q3 20243($1.43)($0.58)($1.14) Q4 20243($1.30)($0.34)($0.95) FY 202412($6.18)($3.11)($5.08) Q1 20251($0.87)($0.87)($0.87) Q2 20251($0.80)($0.80)($0.80) Q3 20251($0.83)($0.83)($0.83) Q4 20251($0.80)($0.80)($0.80) FY 20254($3.30)($3.30) ($3.30)BPMC Earnings Date and InformationBlueprint Medicines last posted its earnings results on February 15th, 2024. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Its revenue for the quarter was up 85.5% on a year-over-year basis. Blueprint Medicines has generated ($8.36) earnings per share over the last year (($8.36) diluted earnings per share). Earnings for Blueprint Medicines are expected to grow in the coming year, from ($5.42) to ($2.95) per share. Blueprint Medicines has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.Read More Blueprint Medicines Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Estimated)------- 2/15/2024Q4 2023($2.04)($1.82)+$0.22($1.82)$67.34 million$71.96 million 10/26/2023Q3 2023($2.39)($2.20)+$0.19($2.20)$50.66 million$56.57 million 8/2/2023Q2 2023($2.58)($2.19)+$0.39($2.19)$45.60 million$57.60 million 5/4/2023Q1 2023($2.66)($2.15)+$0.51($2.15)$41.85 million$63.29 million 2/16/2023Q4 2022($2.73)($2.65)+$0.08($2.65)$33.52 million$38.78 million 11/1/2022Q3 2022($2.51)($2.23)+$0.28($2.23)$43.49 million$65.98 million Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022($2.23)($2.68)($0.45)($2.68)$37.61 million$36.55 million 5/3/2022Q1 2022($1.79)($1.79)-($1.79)$39.98 million$62.70 million 2/16/2022Q4 2021($0.71)($0.99)($0.28)$3.42$104.14 million$107.00 million 10/27/2021Q3 2021($1.63)($2.00)($0.37)($2.00)$42.58 million$24.19 million 7/28/2021Q2 2021($1.77)($1.86)($0.09)($1.86)$28.57 million$27.30 million 4/28/2021Q1 2021($1.80)($1.72)+$0.08($1.72)$24.71 million$21.58 million Blueprint Medicines Earnings - Frequently Asked Questions When is Blueprint Medicines's earnings date? Blueprint Medicines has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on BPMC's earnings history. Did Blueprint Medicines beat their earnings estimates last quarter? In the previous quarter, Blueprint Medicines (NASDAQ:BPMC) reported ($1.82) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.04) by $0.22. Learn more on analysts' earnings estimate vs. BPMC's actual earnings. How can I listen to Blueprint Medicines's earnings conference call? The conference call for Blueprint Medicines's latest earnings report can be listened to online. Listen to Conference Call How can I read Blueprint Medicines's conference call transcript? The conference call transcript for Blueprint Medicines's latest earnings report can be read online. Read Transcript How much revenue does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded annual revenue of $249.38 million. How much profit does Blueprint Medicines generate each year? Blueprint Medicines (NASDAQ:BPMC) has a recorded net income of -$506.98 million. BPMC has generated -$8.36 earnings per share over the last four quarters. What is Blueprint Medicines's EPS forecast for next year? Blueprint Medicines's earnings are expected to grow from ($5.42) per share to ($2.95) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Madrigal Pharmaceuticals Earnings Nuvalent Earnings BridgeBio Pharma Earnings Biohaven Earnings Ionis Pharmaceuticals Earnings Alkermes Earnings Organon & Co. Earnings Intra-Cellular Therapies Earnings Viking Therapeutics Earnings Perrigo Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Lululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later?Is Roku worth a second look after the earnings panic selloff?Dell Technologies breaks out ahead of earnings releaseNovavax’s dispute resolution and upcoming earnings callImpinj stock surges on strong earnings and guidanceAirbnb stock bulls just went all in before earnings This page (NASDAQ:BPMC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.